Latest / Powering the Future Within / Episode 9: "A Front Row Seat to the Unmet Need": How a Leading Physician Became a Serial Innovator
Transcript
- speaker-0: Welcome to Powering the Future Within, the podcast where we explore the breakthroughs shaping the future of med tech. I'm Omari Bachnit, CEO of Resident League Medical. Each episode, we speak with a leader who is driving the next wave of medical innovation, advancing technologies that are smarter, less invasive, and more connected than ever before. This is where the future of health takes shape. Let's dive in. Today's guest is Dr. Stephen Michelson, a physician entrepreneur who has helped redefine the future of cardiac ablation. He is the founder of Feropulse, the company that pioneered pulsed field ablation, a breakthrough technology that is rapidly transforming the treatment of atrial fibrillation around the world. He is now the founder of FieldMedical, where he's continuing to explore new ways to use energy-based technologies. to treat cardiac arrhythmias. Dr. Michelson combines the perspective of a clinician, inventor, and founder, and his work sits right at the frontier of where medicine and engineering meet. Steven, welcome to Powering the Future Within. speaker-1: Thank you for inviting me, Amara- ⁓ speaker-0: This is a true pleasure for me. I'm a real fan of pulse field depletion and how it's really transforming the field. But I'm curious to kind of start back at the beginning to understand what originally pulled you into medicine and at what point did you realize that you wanted to shape technologies? speaker-1: Well, I have a little bit of an unusual background. You know, I didn't start off wanting to be a doctor. I was started off wanting to be ⁓ a professional musician. I had a day job in a hospital for the first decade. I was touring and, ⁓ and, I releasing records. And then, yeah, sometime my day job became much more exciting. And I really loved the, was working closely with a ⁓ cardiac. electrophysiologist named Fred Kusamoto. And, you know, and at that time, you know, there was a lot of innovation ongoing in the EP field. And I became really, I just fell in love with that, technology, the, the, process and, and the constant innovation in that space. And I decided to go to college and get a, ⁓ and then go to medical school after that. speaker-0: So what kind of music with genre were you pulled to? speaker-1: Well, you know, I guess it would be called like college indie alternative, uh, you know, and, you know, if you can imagine the early nineties, um, which were so, so, so long ago, the, uh, uh, you know, uh, you know, there were a couple of bands, um, that, the first band that got signed was a band called the belly acres, um, and college rock. And then, uh, another band called Venus, Yablo, which was more like beatnik, uh, rock. meets progressive theater. speaker-0: Wow. Any particular instruments or vocalist or? speaker-1: Yeah, I was a singer ⁓ and songwriter. wasn't a very good musician, but I surrounded myself with really, really amazing musicians. And, and that's what made it work. speaker-0: Wow, that's fantastic. We'll definitely perhaps have to carve out a little bit of a session where you can stretch your vocal cords and show us what you've got. speaker-1: Yeah, the only person who likes to listen to me sing anymore is my daughter. and she's too young to complain. Or at least one of them is too young to complain. speaker-0: So by training then, then you do decide to pursue medicine and by training you're an electrophysiologist. Maybe you can just describe what that is for those of those who don't know. speaker-1: Yeah. Yeah. Electrophysiology sounds fancy, but it's a heart doctor that specializes in the rhythm of the heart. So the heart has is a pump. has valves that open and close like doors. Its job is to move blood around into the lungs and into the body, but it also has its own electrical system, kind of like the brain does. You know, if you cut out the heart. and you sew it into somebody else, it kind of comes with its own electrical system and its own ability to work. And that's what an electrophysiologist focuses on is treating the problems that arise from the heart going too slow or going way too fast. speaker-0: So the musician was attracted to a field that deals with rhythm. Ha Right on beat. Yeah. So what drew you to that field in particular? speaker-1: ⁓ well, you know, like I said, you know, I, kind of ended up there accidentally. ⁓ you know, I needed, I needed some income when I wasn't touring because, ⁓ I don't know if you know this, but it's very hard to make money as a musician. So, ⁓ but, and I just, happened to work in the ICU and then trained in the calf lab in an era when it was possible to do that without a degree. ⁓ you know, I was on the job training and, know, the doctors took me under their wing and I was just scrubbing in with them and working on started doing research and that research was related to rhythm, ⁓ arrhythmia stuff and, and ablation in particular. ⁓ and so I got to actually meet a lot of the people who were the true pioneers of in the field. Right. speaker-0: And during that time when you were going through electrophysiology training, electrophysiology as a field was still relatively new and novel and there was a lot of innovation coming through and rapidly changing. right. Electrophysiology has been interesting because it's really kind of a combination of art and science, trial and error, not unlike developing music. speaker-1: Yeah, yeah. know, there are a lot of musicians who end up in, and interestingly enough, engineers who are an undergrad who end up in the field of cardiac electrophysiology. And think there's, you know, have to be a little bit nerdy and really enjoy technology in a way that is perhaps not a healthy love of a technology because you're really driven. by ⁓ the tools that are used to achieve things that were impossible to do in the past. mean, literally any arrhythmia was either treated with drugs, which are all toxins that are just, most of them don't work very well and they have a lot of side effects, or you would get open heart surgery and nobody wants that. So minimally invasive procedures evolved over the course of the last 35 years to be something that is almost routine now. but depends heavily on really cool technology. speaker-0: Yeah, yeah. And to that point, I mean, you're treating patients, the field is transforming literally week to week, month to month. Was there any specific patient moment or patients that you encountered that helped inspire you to want to become an innovator? speaker-1: you know, from my point of view, ⁓ the main reason I made the leap was I wanted to be from being, you know, to go to college, get an undergrad degree and be a straight A student. So I can go to medical school was, was the desire to be involved in the development of the technology itself. So it was really my desire to, to, to get, ⁓ the privilege of working on that technology that drove me to become a physician. I learned. to fall in love with being a physician after I had already dedicated my life to the, you know, how to invent things and build better technology. speaker-0: So why not pursue engineering then, for example? speaker-1: You just don't get, you don't get, ⁓ you know, you don't get the front row seat to the unmet need. You just don't get to see where the problems are and ⁓ in the same way. And, know, so solving those problems from afar, you're listening to lots of input. But if you're the one trying to solve the problem for the patient who sits in front of you, which is, know, that's, you know, it's a much stronger connection to understanding where the problem is. And I just thought it would give me a lot more ability to ⁓ have a leg up ⁓ in that innovation space if I was the guy having to put a pacemaker in it, if I was the guy having to move catheters around in the body. And ⁓ it would give me credibility for the science. speaker-0: Yeah, that's a great perspective a front-row seat of the unmet need and a lot of the entrepreneurs and innovators that we talked to and investors quite frankly a lot of the conversation goes back to entrepreneurs wanting or needing to have a front-row seat of the unmet need and really uncovering those unmet needs then is what a lock unlocks What the application could be what the innovation could be to help solve the unmet need so you saw that from? a very early stage, did you have confidence that by seeing that need that you would also then have solutions that you would be able to conceive of? speaker-1: Yeah. And maybe that's, know, I mean, I think you hit on it, Amari, that the, you know, like, yeah, a lot of the entrepreneurs that I know personally, you know, they, the, have a, ⁓ they have an urgency of, of, ⁓ of, know, creativity and thinking and, ⁓ and, to create, you know, they, live with a mission every day. And, you know, solving those problems is just something that that part is just what's coming somewhat naturally as you observe the challenges that are in front of you. I, so, you know, I think, you know, it's, don't think I'm it's unique to me by any means. I think that it's, you know, it is a category of human being who kind of sees, and it may be related to writing songs and painting paintings and that creative kind of, you know, part, but, but the EP space, was a particularly rapidly moving and fertile space for me to start ideating on how could we make it better. speaker-0: Great. So let's talk about pulse field ablation. What is it? speaker-1: ⁓ yeah. So pulse field ablation. What EP doctors do when they're treating tachycardia is they put little catheters up inside the body. Right? So they got to do a couple of things. They got to identify where the problem is, diagnose it. We use ⁓ kind of ⁓ a number of techniques, pacing and recording the electrograms on the inside of the heart and mapping systems and imaging systems. We combine all that to figure out where the problem is. And then we navigate a catheter to that spot and then we deliver energy to destroy the abnormal tissue that's causing the problem. And so, know, ⁓ what pulse field is, is a fancy term. It's a marketing term. ⁓ It's also called DC ablation. It's called fulguration. It's called electroporation. You know, has a lot of names, but it's electric field mediated tissue injury. And so that's a highly technical way of saying, Hey, the, can destroy tissue lots of ways you can use, you know, lasers, ultrasounds, ⁓ freeze it. ⁓ can put alcohol in it. can put, ⁓ you know, chemotherapeutics and talks, the diphtheria toxin and poison arrow frog stuff, you know, whatever, right? There's lots of ways. harm the tissue to create a lesion to destroy abnormal tissue. Pulse field ⁓ is just a way of doing it with very strong electric pulses. And unlike almost every other way that you're going to kill the cell, what you're really doing is you're using very strong electric fields to induce a metabolic injury that the cell dies by depleting its reserves of energy. And that's, ⁓ and this allows for the potential of selectivity and the ability to very, the body to repair and heal much more rapidly. And so there's huge advantages for that energy source that I think people are now starting to recognize. speaker-0: So let's step through that a little bit. So we're discussing about targeting arrhythmias, which are essentially abnormal heartbeats. In this case, you're referring to tachycardia, which would mean an abnormally fast heartbeat. There's a portion of the heart that's really driving that. And as an electrophysiologist, you're targeting the abnormal heart tissue and you're finding a way to neutralize it or to destroy it or to kill it. What you don't want to do is then harm healthy tissue around it. So what pulse field ablation is doing for us is allowing us to really select that tissue that's causing the abnormality. And I think the way that it functions with these electrical pulses is so interesting, targeting the metabolic components, which means that it's sparing a lot of the tissue around it and not harming the healthy tissue. speaker-1: Yeah, it has the potential to spare some of the collateral tissues in a way that thermal injury doesn't and ⁓ certain types of toxins don't. ⁓ you said it very well, which is the promise is that we have this ability to do this, but not only do it safer, have better outcomes, but to do it also in a very time efficient way. ⁓ And, know, so the electroporation or pulse field ablation, you know, when it came into my, my realm of understanding, you know, when I, when I started trying to figure out how to treat a fib in 2011, I really, really saw that as a, um, an important unmet need because as we started seeing more and more of these procedures being done for a nuisance problem, I wanted to make sure that we had a safer and more time efficient way to do it. Because how are you going to treat millions of people if you have in those days? It was a four-hour procedure right and then it's a nuisance problem. So If you have a complication in a scenario like that ⁓ It's a real tragedy because you you so you you really the demands for a very high safety Bar are there you know and so that was a lot of the motivation to look for What are other ways that we can do this besides thermal ablation? then DC ablation from the 1980s is electroporation. When I looked at that, I said, well, why not use this? speaker-0: interesting. speaker-1: But to a modern version of speaker-0: Right. So if you were to do a comparison and we're talking about ablation for atrial fibrillation, there's millions and millions who are suffering from atrial fibrillation worldwide, which is this abnormal heartbeat in the upper chambers of the heart. And one of the reasons why it's important to address atrial fibrillation is that it's highly connected or correlated with stroke events. So. people with atrial fibrillation that are high risk for stroke, and there are different ways that you might be able to help address this. Atrial fibrillation has become one of the predominant ways of doing so. So what would a atrial fibrillation ablation look like in the early days when you were training on it versus how does that look when you're using pulse field ablation? speaker-1: Well, you know, ⁓ when I was a technician working at a hospital with Fred Kusamoto, ⁓ I joked to him that I thought there will never be a bleeding a fit because nobody was. A few people were trying to reproduce what was done surgically with catheters. ⁓ But it was in the late nineties, ⁓ some French physician scientists came up with a solution, which was to isolate the ⁓ areas in the heart. of the left atrium called the pulmonary vein. so the anatomy, there's a place in the heart where we've noticed that people who have AFib, the abnormal tissue that is initiating it and keeping it going and causing the symptoms and all that stuff and all the sequelae of problems that fall out from it, like stroke, et cetera, you know, ⁓ they figured out, ⁓ all you have to do is isolate these sections of the heart and voila. You're done. So early ablation was done with a radio frequency catheter in majority of cases. That's a way of cauterizing or heating up the tissue. And he would just kind of go around the veins point by point by point by point by point. And it took a long time and it took a lot of But as people started doing it more and more, instead of, you know, 50 cases a year, hundreds of cases a year, thousands of cases a year. And then the guidelines came out where it was recognized as boy, this is an important segment of what we do as doctors. We started really seeing where the complications were coming out. And if you're going to treat millions of people, it can't be a complex procedure like that. And so as people got more and more innovative, ⁓ know, the mapping systems got better and ⁓ some tools like the cryo balloon, which is a tool that kind of sticks in the vein and then all on one shot kind of ablates it. You know, that's, that was what was going on at the time that I decided that I wanted to look at how to fix it, you know, how to do it better. It was still a very long procedure. I thought, and what I saw is we're not going to be able to treat all these people unless we get safer technology and we get it. it's sub one hour routine and anyone can do it. speaker-0: fascinating. And so then what's the origin story behind ferropulse, which ultimately was at the forefront of this transformation? speaker-1: Yeah. So, Farapulse started off as a company I called Iowa Approach. So, I was in training at the University of Iowa at the time. I'd gone from undergrad to the University of New Mexico for medical school. Then I went to the Mayo Clinic and I spent some time at the NIH as a Howard Hughes research scholar when I was there. then, and then after Mayo Clinic, I came to the University of Iowa. I kind of knew EP. before I even started the process, but you know, during that time in Iowa, I ⁓ had a couple of technologies I had thought up and was inventing and I ended up getting funded to do ⁓ this new technology for treating atrial fibrillation. ⁓ And I needed to apply for an SBIR grant. And you know, this is kind of boring, but it was out of necessity. The university asked me to start a company and license my technology back to that company and try to develop it because it's one thing to have an idea, but it's another thing to shepherd the idea all the way to market. ⁓ And that was an exciting proposition to me. ⁓ so, so, Fairpulse kind of grew out of Iowa Approach, which was a, ⁓ I built the generator, I built the catheters, and then I started hiring people. raising money with some, ⁓ and with some early help from ⁓ a friend of mine, John Slump, and ⁓ hired a guy named Eric. And then eventually I realized, you know, I needed to bring in ⁓ a professional CEO to drive, drive success of the technology. So I sought out and find, found a guy, Alan Zingler, and, you know, hired a bunch of people and then Uh, and we changed the name, uh, and the reason it was called Iowa approach is because as an entrepreneur, I had to raise money in Iowa. I want to make sure people kind of, yeah, identified, know, the farmers who are going to invest in this area, you know, they identified it as, know, a good investment for their Iowa roots. Uh, and the, but that's, you know, the birth of, uh, Fair Pulse was quite interesting because, uh, you know, I ran it for about two and a half years myself. speaker-0: Ha ha ha. Guys. speaker-1: And then I brought on Alan and you know, we, got a large investment from Boston scientific early on, very supportive and ultimately sold the company to Boston scientific. speaker-0: And now if you look at PFA even more broadly, it's become one of the most rapidly adopted new technologies in the history of all of med tech. mean, there are some real great stories out there about adoption, but I think it probably rivals the adoption of drug eluding stents, for example, in interventional cardiology as one of the most rapidly adopt modalities. How does that? speaker-1: Well, look, I was around, I was working in the cath lab as a technician in the era of the last waning days of twilight of plain old balloon angioplasty. And so I got to see the impact of, of, of a truly disruptive technology on, on, on the hospital. You know, maybe that was part of the inspiration, but why, ⁓ fair pulses like that, you know, why pulse field and in particular. A number of the companies were working on it at the, at the time I wasn't alone, but, but fair pulse was really the first person to challenge the standard, ⁓ and say, Hey, you know, we, we're going to take it all the way to market, whether you, whether you think it's good or not. And then people started when they saw the results in the clinical trial, ⁓ they saw the value proposition, which is. You can do this really fast. It's democratizing. So almost any, any doctor who does EP can do it and it's safer and is pretty rare in the world of med tech innovation, where you have something that has a dramatic impact on workflow without compromising something. So this technology not only had the promise of being safer, less esophageal injury, less phrenic nerve injury, less pulmonary vein stenosis, all those things that have been plaguing the field. But also now we got sub one hour routine afib ablation available. So now we can do twice as many cases, if not more than we could in past. in other words, you know, we've opened up the floodgates for, ⁓ to address more patients because EP doctors take forever to train and hospital infrastructure takes forever to kind of to grow. But boy, if you can take a procedure and take it from four hours to one hour, now you've really opened up access for patients who can benefit from the procedure without compromising the safety. And I think that's really what drove what was just a phenomenal ⁓ transformation in the field. mean, literally overnight, thermal ablation is just falling off the map and we're moving towards pulse field in almost every every part of them. speaker-0: Yeah, it's truly amazing. And I think one of the other aspects of the characteristics that driven the adoption is that it doesn't really require the physician to adopt a new workflow. The learning curve is very low. So this burden of learning is very low. And you add that with the efficiency and then especially the safety profile, it's really set up to be a widely adopted technology. speaker-1: Yeah. And you can see the success of the, the fast followers that are out there. Like, you know, there's a lot of pivots and even those pivots are substantially better than their original applications. And, you know, and so it's, it's really exciting to see the, you know, the, you know, this explosion and innovation in the space that I, that I absolutely love, which is arrhythmia management and electrophysiology. speaker-0: So was there a moment or a procedure where you said to yourself or out loud, this will be a game changer, will be disruptive for these reasons? Was there a moment in time or an observation early on where you really became compelled or convicted because of something you observed? speaker-1: Yeah, well, ⁓ couple of things. Now, for Farapulse in the early days, in the Iowa approach days, I saw the promise of ⁓ the energy, the promise of the procedure ⁓ and the goals. And I knew people who had been harmed by complications. ⁓ There is a story in my, like I've started a couple of companies and ⁓ there is a company I started that is a direct result of something very personal that my brother ⁓ died from a complication of a biopsy. Simple biopsy, know, putting a needle in trying to get a piece so that you could look at it under a microscope, but they hit an artery and ⁓ it didn't end well. I started a company called Needle Eye ⁓ to try to address that by creating a tool that would allow you to see what's in front of the needle as you advance it through the body. So whether you're going after a biopsy or vascular ⁓ access, that would be it. And so that can really drive fire in you to innovate. Every entrepreneur kind of falls into this space where anything you're working on is the greatest thing on. on earth, you know, and it's got to be obvious to everybody. This is amazing, right? Oh, and but you know, in the early days, you know, the innovation and the speed and the excitement surrounding it, you know, I thought it would have a normal adoption. did not expect to see to see the you know, you know, something, you know, early adopters and then kind of this organic growth afterwards. No, no, it was it was it was truly a disruptive technology. And I did not I did not predict that level of excitement, in the early days. speaker-0: So that was even a surprise to you as an entrepreneur who was completely bought in. speaker-1: Yeah. You know, and some like I predicted a lot of the challenges we would see and the complications and the, you know, the anticipated chat, you know, you know, ⁓ issues that would arise with this, but I missed a few that really surprised me. ⁓ you know, there's been more of an issue with hemolysis than, I should, I, you know, I kicked myself in the butt for not kind of anticipating that. Um, and, know, uh, you know, and, and, you know, some, some of these issues with late, uh, vasospasm, which are very rare, but, know, everyone is scratching their head right now. And like, Oh, those are the things that we're talking about as, as, uh, doctors who are kind of seeing this transformation in the field and this six, this rapid adoption. But you know, what we're, what we're walking away from is massive. challenges with esophageal injury and phrenic nerve injury and all these things that we used to have to deal with, ⁓ you know, close to a one, you know, half a percent or 1 % of people, know, so it's, it's, ⁓ we've moved the bar of safety substantially in the right direction, but we're not out of the woods. speaker-0: Yeah, yeah. No, we always want to focus on improvement. How do we get better? But I always think about Maslow's hierarchy of needs and you start with from a safety perspective, what are the implications around mortality? And then you kind of move from there and it definitely feels like we've moved the ball. You know, something like an esophageal injury during ablation can be catastrophic. ⁓ if you've ever had spoken to a physician who encountered an esophageal fistula, You know, that can be catastrophic. know, friend nerve injury can be highly problematic and you're, you're able to progress from those to, you know, safety concerns that maybe are less life threatening, you've certainly advanced the ball quite a bit. speaker-1: Exactly. I mean, I'm pretty proud to be a part of that story. But boy, there's a lot of people who are part of that story. It's kind of fun to see that first generation of technology making a difference, ⁓ making a real difference in people's lives. speaker-0: Yeah, success has many parents and I think that probably has to be part of the joy of the journey is doing it together with a team, right? speaker-1: Absolutely. speaker-0: So you go to this exercise, you have tremendous success, and it feels like that's really filled your cup to want to continue to pursue innovations and continue to explore unmet needs. Very personal story with the situation with your brother, but you kind of understand how this innovation ⁓ engine works. I wanted to talk to you a little bit about the transition. Many physicians struggle with a leap from clinician to executive. you always kind of had the intention of working on innovation. Was there anything difficult for you about the transition and any advice that you would give to other clinicians who are considering working on innovation? speaker-1: Yeah, you know, ⁓ it is, it is, ⁓ incredibly challenging. You know, one of the things that I have a lot of physician friends who are inventors and very, very smart, talented, and in, you know, in lockstep with, with the needs of the field and what needs to happen next. There are a lot of doctors out there who are really good at figuring out what is the next step. in technology that we need today, right? But when they want to like, and then, and they want to kind of make the leap into, you know, being an entrepreneur, starting a company, taking their idea and, and, you know, and, ⁓ and stewarding it to a commercial reality, you know, that's, that's a much bigger leap. And, and so I usually kind of, I, I talk a lot about to, fellow physician inventor entrepreneurs, you know, that the things that I've learned, you know, ⁓ you know, that fundamentally, you know, doctors have a different skill set than business people. ⁓ You know, we train in the interventional space of doctors in particular, to really make high stakes decisions, ⁓ you know, that's ⁓ quickly. And often without the luxury of consensus, you know, you got a patient in front of you that might be dying. You got to make a decision, fix it and move forward. And, you know, and so doctors are just full of executive function. Their ability to move quick and make decisions and choose a path forward. Great. But the executive role ⁓ often ⁓ is a different ⁓ skill set, right? Different type of training. You're dealing with organizations and consensus building and teams. ⁓ you need a, ⁓ you know, much like a scientist, physician, scientists would do, you have to build, you know, a justification and story behind whatever you're doing, you know, but, you know, being savvy in, ⁓ in contracts, in fundraising and all those things, the blind spots are glaring. and so it's hard to be good at everything. And so I've, I've met a few people who seem to be, but I'm not one of them. And so there was a lot of hard lessons. and so when I talked to clinicians about, you know, moving to that role of, of startup, you know, I, ⁓ you know, I, I usually say, you know, pay a lot of attention to finding ways to understand your own blind spots and, and then surround yourself with the people who are really good at it. Cause it's going to take you time. If you're a first time entrepreneur, it's going to take you time to see it play out and how. people approach these questions and these problems. You're good at the technology, but are you good at the operations of a startup? so my, my advice for most guys is if you're crazy enough to jump in and just go, go for it, then you know, I support you, but be ready to, you know, to, to lay yourself bare in front of all your own deficiencies. And, and that was my experience as a physician. jumping to the next stage. Luckily, you know, my first experience, I recognize I didn't have the skills to be a CEO. So I brought one on, you know, and, and then I worked with a lot of startups and a lot of technology and engage in it, became an executive at a company and learned and learned and learned. ⁓ and that's what I think led to a lot of the success that we've had at field is that I jumped into field with a heck of a lot more experience. speaker-0: Yeah, but that takes a lot of self-reflection to identify that. And I find it fascinating what you mentioned about physicians, particularly those who are operators being filled with executive function and how important that is in the operating room or the cath lab or the EP lab. But you step into an organization where you have to drive consensus building. And you can run into issues very quickly. So having that type of self-reflection to compare the two environments, I think is very important. And as you mentioned, so you've continued on with innovations and pulse field ablation. Tell us about field medical. speaker-1: ⁓ Field Medical is my favorite company of all time. speaker-0: Ha ha ha ha ha. speaker-1: Um, yeah. So, uh, when I was, uh, you know, so I was practicing at Scripps Medical Center and, I still have, uh, an appointment at the university of Iowa and, uh, and I took a, uh, an executive, uh, position at, uh, at Acutus Medical, which is a mapping and, uh, um, you know, EP technology ablation, uh, uh, company and, uh, and help them to take a catheter that they already had and. converted into ⁓ an ablation catheter. So as that program was winding down, because there was some issues with the runway of that innovation in the market, ⁓ I stepped out of the company ⁓ to address what I saw as the big, one of the biggest remaining unmet needs in electrophysiology, which is we have technology that's good at treating the atria. In fact, you know, Farapulse is damn good at treating atrial, you know fibrillation. And so where is the big unmet need? It's in the ventricle. It's in the bottom chambers. And those are the deadly arrhythmias. Those are the ones that are just hard to treat. Those are procedures that take four hours on average now. Like, so it's a lot like what a fib was like in 2011 when I first started trying to solve that problem. And so I see it resonates with me and I'm all, and then if you look at pulse field, this first generation of pulse field, you know, is good. It's amazing. But the first time I ever got to do a patient with my own technology with ferropulse, I put it in and I had been working for the last 15 years to learn everything I can about how to optimize it, how to make it better, how to apply it. And I felt it was a little old fashioned. It felt kind of 10 years old. And, ⁓ and so when I just knew that Boy, there's just so much more we can do with PulseField than we currently have. And I know it looks like it's been super transformative and everything from here on out, it's going to be small incremental improvements. But I saw an opportunity to show the world that not only that we could make another big leap in the, you know, the platform itself in PulseField, get it. for the first time ever. have an effective tool to treat these deadly arrhythmias. speaker-0: So you're targeting the lower chambers of ventricles, targeting these deadly arrhythmias, and the tissue in those lower chambers is a lot thicker. So there must be some aspects of the technology that you've modified for that deployment or that application. speaker-1: Yeah, yeah. mean, ⁓ atria is pretty thin, you two millimeters, max maybe five millimeters in a few spots. ⁓ It's pretty smooth. Most of the chamber is pretty smooth. So it's, you know, it's kind of predictable and it doesn't move a lot. know, like parts of it will kind of move. It takes blood in and lets it move into the bottom chambers. The ventricle is highly irregular, super thick, and it moves centimeters with every contraction of the heart. And so to get stability and to move around in there, and then you have complex structures called trabeculae and, and, you know, and then the cordae of the bowels and things just get in your way. It's a, a very challenging environment for the historic tools to work in now. Good news. We've been using those tools for decades and we have the most, you know, we can treat patients really well, but it just takes a lot of skill and a lot of time. And, uh, and so pulse field, if you. to get that depth, to get full transmirality in some cases, or at least get very, very deep, you know, ⁓ the electric field is like a gravitational field. And the best way to reach deep is to have very high voltages. And so instead of this 2000 volt kind of stuff that's typical of the first generation PFA, I decided to make a big leap. And, and, and. go way up in voltage. that has been really helpful here for you reaching deep. speaker-0: Were there new considerations you had to take into account when you increased the voltage to those levels? speaker-1: What's counterintuitive to most people is that by increasing voltage, we can actually decrease the total energy. So I use less energy. just, it sounds big, but remember if you ever grew up in a family with a brother, right? Like, you know, ⁓ did you ever like shock each other with static shocks? Like you just kind of, yeah, you kind of get it. ⁓ you get yourself all charged up and then zap your little brother or whatever. Right. You know, so I grew up, ⁓ I had some brothers and so, and I wasn't the oldest one. So I tended to be the rec on the receiving end of that, but that's like 60,000. Right. So that static discharge is very high. So high energy, mean, high voltage, but low energy is actually something you can take advantage of when you're trying to tweak the cells, ⁓ and get the precision and get the versatility. And that's where this next generation of pulse field. speaker-0: Volts. Yeah. Yeah. speaker-1: I think is going to go, you know, there are big challenges, technical challenges to achieving that. But, know, you know, but, you know, thank God I'm surrounded by some really amazing engineers who helped there. you know. speaker-0: So you've increased the voltage, but then you've decreased dramatically the delivery. speaker-1: Yeah, the delivery time is a lot faster. Like, ⁓ it's a blink of an eye. ⁓ you know, so different recipes, right? Like the one that we have in the ventricle, we repeated a few times. So one spot, zap, zap, zap, zap, and then move it and zap, zap, zap, So, but it, and instead of being a four hour procedure, we see visibility on having VT ablation be kind of someday be a routine, a one and a half hour or even a one hour procedure. because we're taking away a lot of the unknowns and the challenges that we currently face. And the clinical trial results from the pilot study we did, you know, got published in circulation, I think largely because it's one of the most successful VT ablation trials ever run. A small sample, but I'm super proud, super proud of that. speaker-0: Yeah. So then what's next? Are you moving towards larger clinical trials at field or what's next? speaker-1: So field is conceived as really, I like to think of it as the true kind of, you know, the culmination of all my knowledge, all these years working in Pulse Field. And so it's a platform technology that can really do the ventricle really well. But we immediately ran a trial in AFib as well. And so, so that we could show people that it's the versatility of the platform. So field has expanded beyond the ventricle to also include ⁓ trial work. showing the value for, ⁓ you know, ⁓ atrial fibrillation in particular, but any arrhythmia where you need the versatility of a focal catheter. So that's, that's it. You know, that's the main thing, ⁓ in that field is focused on. And this year we're going to start our, ⁓ our, ⁓ our pivotal trial, our FDA trial. So we've got breakthrough status. got it into the TAP program. You mean you couldn't ask for, a better. Yeah. Experience in the world of startups, you know, companies funded, you know, it's all that stuff. speaker-0: was very exciting. And I also find it fascinating that you've started exploring some work with PFA outside of the heart as well with Dell Meta. speaker-1: Yeah. So Dell MedSec. So, I mean, here's the short story about that, which is, you know, it's over the last five years, there's been probably $5 billion, if not more, poured into the R &D surrounding cardiac, PFA, ablation, innovation, learning everything we can about how to optimize this for delivery in a very challenging part of the body. ⁓ but it turns out, you know, if you really go back in the history of electric field mediated tissue injury technology, ⁓ you know, you go back to the 1800s, they're doing this thing called full duration. go back to the early eighties, they're doing, you know, pulses. But you know, there were DC pulses and things like that. but the place where electroporation or ⁓ fulcration was used was cancer. And there's been some interest out there, but there just hasn't been the level of science and innovation ⁓ that we have in cardiology. So cardiology is a cauldron of innovation that's well-funded and all that knowledge could be applied to all the other parts of the body where we currently do ablation with thermal tools or other tools, right? And there's already a number of people working on prostate, there's the ENT, there's ⁓ some GI applications. And I look at that and I say, well, boy, can we take what we've learned ⁓ in our space and especially with the type of generator that field has built, and can we apply that to problems outside the heart and transform those areas as well? And my answer is yes. That's Del McTuff. speaker-0: Yeah, that's really, really exciting. again, going back to this concept of having a front row seat of the unmet need, from a clinician's point of view, are there other emerging spaces or technologies outside of PFA that excite you? speaker-1: ⁓ yeah, yeah, yeah. I'll put in a, you know, needle eyes one of them. A company I helped start with Eric Sauter and ⁓ John Slump was called A-H-R-Verse, which has just entered the market. It's a radio frequency crossing wire. So it helps you to get from the blue blood side of the heart to the red blood side of the heart to do all these types of procedures to put in. If you're doctor, he's going to put in a ⁓ left atrial appendage closure tool. If you're going to do a mitral clip to close the mitral regurgitation or a number of other procedures are done there. And yeah, that's exciting. I personally, I'm deeply interested in a ⁓ number of kind of cool medical technologies that I've seen out there. But if I, ⁓ if we were to sell. field and I, you know, and, it was me in the market and I could focus my attention on the next big thing. I don't know. I might go into space propulsion. Right. You know, cause like, you know, the guys who are, you know, I really like the high voltage aspect of ion drives and I'm kind of a nerd like that. And it would be fun to kind of get out of the medicines world and go out. into space and compete with Elon Musk and those guys, they don't know what they're doing. speaker-0: Space propulsion, okay, we'll stay close to that. ⁓ I'm curious as you've transitioned out of clinical practice just within the last year or so, and part of your motivation was to have that front row seat. How do you maintain that view into unmet needs in the clinical environment? speaker-1: ⁓ it'll become harder. Yeah. It'll become harder. ⁓ you know, I hope that, that, that I have enough momentum, ⁓ that, ⁓ that that front row seat, ⁓ even if I'm sitting in the second row, I'll still have access in a way, you know, I'm involved in, you know, I know, you know, I, I go to the procedures and, know, I'm hoping that, you know, that my. My spidey sense of med tech need remains strong, but it may not, you know? And so, you know, as, as I transition into more and more of a, you know, kind of a, you know, company building kind of role, uh, you know, uh, I'm going to be relying and leaning heavily on my friends who remain in practice. speaker-0: Yeah, and I can imagine in the circles you run in, must get phone calls weekly about concepts, ideas that are worth exploration. And now that you've gone through the cycle a few times, your ability to kind of really go deep and understand what they're seeing is probably very well tuned. speaker-1: Yeah, I feel confident about that. ⁓ And ⁓ I really enjoy talking to fellow doctors, even outside like the topics that I have no idea, sit down with a urologist or something and they tell me what their problems are and what their challenges are and what their vision is of how to make it better. You know, that's a lot of fun to kind of be in that stage of idea. ⁓ ⁓ creation and give them some advice. ⁓ you know, I'll say most doctors are, ⁓ don't want to give up practice to, jump in. They don't mind dipping their toe in, in the water a little bit, but there are a few of them out there that I know that got bold enough and really did it. ⁓ and I've, and, very few of them maintained two halves for any amount of time. speaker-0: Well, and so what's some advice that you would give to a physician or clinician who's considering starting a company? speaker-1: ⁓ there's a lot of advice there. Where to start? ⁓ yeah. No, I mean, you know, the reality kind of boils down to, know, if, if you have the fire to work 24 seven all the time on your idea and moving it forward, you know, then, ⁓ that's the first thing, right? you have to have that energy that, that, that, ⁓ in order to kind of And, and, and the belief in the mission to take it from, you know, concept to commercial. The hard part is, you know, ⁓ you know, so when I, when I talk to the, when I talk to people who would be first time physician inventors who want to do this, ⁓ I kind of just bring them through a lot of the, the, the scars that I've developed, a lot of the pain points. ⁓ and, know, and I kind of make them really, you know, nothing. we'll get to the finish line. If you don't know exactly how you're to make money on it, not you, but somebody has to make money on it. and you know, they, and cause a lot of ideas are great ideas, but there isn't a way to like, you know, if the margins aren't there and all those things like they, they, make them work backwards from how do you picture this rolling out and what would it cost to do this? And Those are things that most of the doctors don't actually think about early on. ⁓ And I like to kind of bring those realities starkly into focus for them from the beginning. then, you know, but it's, really like MBA pitch contest kind of stuff, you know, because once they start seeing the challenges of taking an idea from concept to, to clinic, you know, especially if it's a class three device or something like that. I would highly recommend nobody ever work on a class three devices. ⁓ but, but that, but you know, once, once if, if that hasn't like doused their fire of excitement, ⁓ then they're ready to go. And, and it's just, it's just nonstop hard work. speaker-0: Right. So that's a, that's a good gut check, ⁓ in terms of some level of readiness for commitment, because there's, there's great reward on the other side in terms of really bringing something to market that has a transformational impact on society and on patients. But it comes with a lot of challenges and a lot of effort to get there for sure. For sure. speaker-1: Yeah, when I started of, I will approach variables, you know, when I started that company, I went out to raise money and I, I told people that they were investing in it. was a philanthropic investment and it didn't really play very well with investors. speaker-0: Shockingly. Shock. speaker-1: And so, pretty much you got to figure out how you make money and have an honest way. Because I mean, don't know many doctors who have $100 million to put into a med device company. You're going to have to go out and get it somehow. speaker-0: Yeah, yeah. So at the end of the day, what's more difficult being an aspiring musician or being an aspiring med tech entrepreneur? speaker-1: Uh, I would say entrepreneurs harder, uh, the, but med, well, musician is sort of an entrepreneur. Uh, as a matter of fact, I think I, uh, some of my business skills really came out of that. I never thought of myself as a business guy, but we're doing contracts and I had to, you know, heard, heard the sheep and of my, my bandmates and get them onto the road and book stuff and keep people fed and gas in the car and like, you know, man, maybe that helps. fuel ⁓ my success here. yeah, think the realities of, you it just takes a lot of experience to see ⁓ the vision of ⁓ a startup and jump it and make it work. I think it's a lot harder than what I did as a musician. speaker-0: But it's amazing how things have come full circle and now seeing where PFA is and where PFA is going, it must be incredibly rewarding. Again, one of the most transformational innovations in cardiology in decades. speaker-1: Yeah, I'm very proud to be a part of that story. speaker-0: Well, this has been a tremendous conversation. Thank you so much for coming on and sharing your experience and your perspective. I really, really enjoyed it. speaker-1: Well, thank you, Amari. I hope to see you at LSI. speaker-0: Yes, we'll see each other here soon. And thank you all for joining us today on Powering the Future Within. If this conversation inspired you, follow the show and share it with your medtech community. I'm Umari Bachnit. Stay inspired and keep innovating.